APUS · Apimeds Pharmaceuticals US, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $901.1K | - | $619.7K | $651.8K | - | - | - | - |
| SG&A | $11.28M | - | $300.0K | $427.8K | $271.7K | - | - | - |
| Total Operating Expenses | $364.4K | - | $300.0K | $2.66M | - | - | - | - |
| D&A | $20.0K | - | - | - | - | - | - | - |
| Operating Income | ($12.19M) | - | ($300.0K) | ($427.8K) | ($271.7K) | - | - | - |
| Interest Expense | $8.4K | - | $32.6K | $3.1K | $26.9K | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | ($35.06M) | - | ($332.5K) | ($449.4K) | ($296.5K) | - | - | - |
| EPS - Basic | ($2.26) | - | ($0.40) | ($0.60) | ($0.40) | - | - | - |
| EPS - Diluted | ($2.26) | - | ($1.40) | ($2.60) | ($0.40) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $979.5K | $1.64M | $6.99M | $8.74M | $250.3K | $3.5K | $410.5K | $6.2K |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - |
| Current Assets | $13.15M | $13.98M | $9.09M | $10.35M | $259.9K | $13.1K | $422.1K | - |
| Total Assets | $141.22M | $164.18M | $9.25M | $10.55M | $259.9K | $13.1K | $422.1K | - |
| Current Liabilities | $14.58M | $10.71M | $1.09M | $809.0K | $1.77M | $1.02M | $123.3K | - |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $14.70M | $10.84M | $1.09M | $809.0K | $2.02M | $1.37M | $390.2K | - |
| Stockholders' Equity | $126.52M | $153.35M | ($1.05M) | ($714.0K) | ($1.76M) | ($1.36M) | $31.9K | ($713.6K) |
| Retained Earnings | ($45.45M) | ($10.39M) | ($9.24M) | ($7.46M) | ($4.79M) | ($4.39M) | ($3.00M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.07M) | - | - | - | ($263.1K) | - | - | - |
| Investing Cash Flow | $490.6K | - | - | - | - | - | - | - |
| Financing Cash Flow | $920.0K | - | - | - | $267.2K | - | - | - |
| CapEx | $9.4K | - | - | - | - | - | - | - |
| Free Cash Flow | ($2.08M) | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.06 | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -24.8% | - | -3.6% | -4.3% | -114.1% | - | - | - |
| Return on equity | -27.7% | - | 31.8% | 62.9% | 16.8% | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 0.90 | 1.31 | 8.34 | 12.79 | 0.15 | 0.01 | 3.42 | - |
| Quick ratio | 0.90 | 1.31 | 8.34 | 12.79 | 0.15 | 0.01 | 3.42 | - |
| Cash ratio | 0.07 | 0.15 | 6.41 | 10.80 | 0.14 | 0.00 | 3.33 | - |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | -1452.9x | - | -9.2x | -138.8x | -10.1x | - | - | - |
| Equity multiplier | 1.12 | 1.07 | -8.84 | -14.77 | -0.15 | -0.01 | 13.24 | - |
| Liabilities / Assets | 0.10 | 0.07 | 0.12 | 0.08 | 7.77 | 105.01 | 0.92 | - |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | 0.2x | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -4384.6% | - | - | - | - | - | - | - |
| Net income growth (YoY) | -11725.6% | - | - | - | - | - | - | - |
| EPS growth (YoY) | -465.0% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Apimeds Pharmaceuticals US against the 5 most active filers in the same SIC group.